Management of vaccine-induced thrombosis and thrombocytopenia

There are increasing reports of a rare adverse event of thrombosis and thrombocytopenia following the first dose of the AstraZeneca COVID-19 vaccine, a syndrome labelled vaccine-induced thrombotic thrombocytopenia syndrome (VITT). The colleges and surgical specialty associations have produced guidance on the features and management of VITT, taking into account vascular, gastrointestinal and neurosurgical considerations.

Neurosurgical

• Management of cerebral venous sinus thrombosis following Covid-19 vaccination A neurosurgical guide

Gastrointestinal

• Diagnosis and management of gastrointestinal manifestations of vaccine induced thrombosis & thrombocytopenia (VITT) syndrome

Vascular

• Management of thromboembolic events following COVID-19 vaccination